Loading

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6

BRIDGEWATER, N.J. , July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its

Menlo Therapeutics Announces Pricing of Offering of Common Stock

BRIDGEWATER, N.J. , June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the pricing of an underwritten public

Menlo Therapeutics Announces Proposed Offering of Common Stock

BRIDGEWATER, N.J. , June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it intends to offer and sell,